News Releases

Oculis to Present at Bank of America Global Healthcare Conference

Oculis Publishes Invitation to the Annual General Meeting

Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market

Oculis Mourns the Loss of Chief Scientific Officer Professor Ramin Tadayoni

Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market

Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development

Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Oculis to Participate at Upcoming April Investor Conferences

Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress

Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments